


PHARMACEUTICAL 2018

Sio Gene Therapies Inc. Rank 256 of 349





PHARMACEUTICAL 2018

Sio Gene Therapies Inc. Rank 256 of 349

The relative strengths and weaknesses of Sio Gene Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sio Gene Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 133% points. The greatest weakness of Sio Gene Therapies Inc. is the variable Net Income, reducing the Economic Capital Ratio by 190% points.

The company's Economic Capital Ratio, given in the ranking table, is -373%, being 95% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	219,688
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,266
Liabilities, Non-Current	51,436
Other Assets	2,709
Other Compr. Net Income	378
Other Expenses	430
Other Liabilities	0
Other Net Income	0
Property and Equipment	142
Research and Development	134,800
Revenues	0
Selling, General and Administrative Expense	45,721

Output Variable	Value in 1000 USD
Assets	222,539
Liabilities	97,702
Expenses	180,951
Stockholders Equity	124,837
Net Income	-180,951
Comprehensive Net Income	-180,762
Economic Capital Ratio	-373%